Cardiovascular–kidney–metabolic syndrome
The 2026 AHA/ACC/ADA/ASN guideline is the first to manage obesity, diabetes, CKD and cardiovascular disease as one syndrome, staged 0–4.
Clinical pearls
- Stage 1 adiposity, 2 metabolic risk factors or CKD, 3 subclinical CVD (CAC ≥100, pre-HF), 4 clinical CVD.
- SGLT2i and GLP-1-based therapy are the backbone across stages.
- CKD: RASi → SGLT2i → finerenone → GLP-1 RA.